BrightView Holdings, America’s Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $10
Morgan Stanley analyst Matthew Harrison maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $15 to $10.
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $32
RBC Capital analyst Luca Issi maintains Editas Medicine (NASDAQ:EDIT) with a Sector Perform and lowers the price target from $40 to $32.
SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $12
SVB Leerink analyst Mani Foroohar maintains Editas Medicine (NASDAQ:EDIT) with a Market Perform and lowers the price target from $14 to $12.
Editas Medicine Q3 EPS $(0.81) Beats $(0.86) Estimate. The Company Reported Collaboration Revenue Of $42K
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.86) by 5.81 percent. This is a 42.11 percent decrease over losses of $(0.57) per share from
Traders Circulate ‘Struggling Editas Shops Preclinical Cancer Pipeline During Its Big Makeover’ – Endpoints News
EXCLUSIVE: Struggling Editas shops preclinical cancer pipeline during its big makeover – Endpoints News (endpts.com)
Barclays Maintains Equal-Weight on Editas Medicine, Raises Price Target to $17
Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $16 to $17.
BMO Initiates Coverage On This Gene Editing Spearhead
BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says…
Goldman Sachs Maintains Sell on Editas Medicine, Lowers Price Target to $8
Goldman Sachs maintains Editas Medicine (NASDAQ:EDIT) with a Sell and lowers the price target from $10 to $8.
Editas Medicine’s Return On Capital Employed Insights
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.